-- Health care stocks were flat to higher premarket Tuesday, with the iShares Biotechnology ETF (IBB) up 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) inactive.
Novo Nordisk (NVO) has received the Medicines and Healthcare products Regulatory Agency approval for a new single-dose 7.2 mg of Wegovy to treat adults with obesity, the UK regulator said. Shares of Novo Nordisk were up more than 3% pre-bell.
Johnson & Johnson (JNJ) stock was down more than 1% after the company posted a decline in Q1 adjusted earnings.
Genmab (GMAB) shares were up more than 2% after the company reported Q1 DARZALEX net sales Tuesday of about $4 million, including $2.2 million in the US and $1.8 million in the rest of the world.